Pharmacokinetics of intravenous and oral midazolam in plasma and saliva in humans: usefulness of saliva as matrix for CYP3A phenotyping

Authors:
  • MHManuel Haschke
    Manuel Haschke

Abstract
WHAT IS ALREADY KNOWN ABOUT THE SUBJECT • Midazolam is a frequently used probe drug for CYP3A phenotyping in plasma. Midazolam and its hydroxy‐metabolites can be detected in saliva. WHAT THIS STUDY ADDS • The concentrations of midazolam and its hydroxy‐metabolites are much lower in saliva than in plasma, but the midazolam concentrations in both matrices show a significant linear correlation.• Saliva appears to be a suitable matrix for CYP3A phenotyping with midazolam, but very sensitive methods are required due to the low concentrations of midazolam and its hydroxy‐metabolites.AIMS: To compare midazolam kinetics between plasma and saliva and to find out whether saliva is suitable for CYP3A phenotyping.METHODS: This was a two way cross‐over study in eight subjects treated with 2 mg midazolam IV or 7.5 mg orally under basal conditions and after CYP3A induction with rifampicin.RESULTS: Under basal conditions and IV administration, midazolam and 1′‐hydroxymidazolam (plasma, saliva), 4‐hydroxymidazolam and 1′‐hydroxymidazolam‐glucuronide (plasma) were detectable. After rifampicin, the AUC of midazolam [mean differences plasma 53.7 (95% CI 4.6, 102.9) and saliva 0.83 (95% CI 0.52, 1.14) ng ml−1 h] and 1′‐hydroxymidazolam [mean difference plasma 11.8 (95% CI 7.9 , 15.7) ng ml−1 h] had decreased significantly. There was a significant correlation between the midazolam concentrations in plasma and saliva (basal conditions: r = 0.864, P < 0.0001; after rifampicin: r = 0.842, P < 0.0001). After oral administration and basal conditions, midazolam, 1′‐hydroxymidazolam and 4‐hydroxymidazolam were detectable in plasma and saliva. After treatment with rifampicin, the AUC of midazolam [mean difference plasma 104.5 (95% CI 74.1, 134.9) ng ml−1 h] and 1′‐hydroxymidazolam [mean differences plasma 51.9 (95% CI 34.8, 69.1) and saliva 2.3 (95% CI 1.9, 2.7) ng ml−1 h] had decreased significantly. The parameters separating best between basal conditions and post‐rifampicin were: (1′‐hydroxymidazolam + 1′‐hydroxymidazolam‐glucuronide)/midazolam at 20–30 min (plasma) and the AUC of midazolam (saliva) after IV, and the AUC of midazolam (plasma) and of 1′‐hydroxymidazolam (plasma and saliva) after oral administration.CONCLUSIONS: Saliva appears to be a suitable matrix for non‐invasive CYP3A phenotyping using midazolam as a probe drug, but sensitive analytical methods are required.

This publication has 36 references indexed in Scilit: